Praxair Cancer Center Ninth Annual Cancer Symposium
Advances In Lung Cancer:
Treatment & Detection
The conference is dedicated to the discussion of current advances in lung cancer screening and treatment.
At the conclusion of this educational activity, participants should be able to:
- Describe the most common molecular abnormalities in lung cancer
- Explain the predictive and prognostic relevance of EGFR mutations
- Explain the predictive relevance of ALK rearrangements
- Describe future molecular targets in lung adenocarcinoma and squamous cell lung cancer
- Review new guidelines for lung cancer screening
Gregory Riely, MD
Memorial Sloan-Kettering Cancer Center
Internists, Primary Care Physicians, Medical Oncologists, Pathologists, Pulmonologists, Radiation Oncologists, Radiologists, Other Specialists, Residents, Physician Assistants, Registered Nurses and Other Health Care Professionals.
||Gregory Riely, MD
Molecular Testing for Non-Small Cell Lung Cancer:Current Standards & Future Possibilities (Incl. Q&A)
||Donald Hulnick, MD: Screening for Lung Cancer
||Michael Cohenuram, MD
Summation & Final Questions
Danbury Hospital is accredited by the Connecticut State Medical Society to sponsor continuing medical education for physicians.
Danbury Hospital designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Danbury Hospital is an Approved Provider of Continuing Nursing Education by the Connecticut Nurses Association, an Accredited Approver by the American Nurses Credentialing Centers Commission on Accreditation. Registered Nurses who attend the entire program will receive 2 contact hours.
October 31, 2012
John C. Creasy Auditorium
24 Hospital Avenue
For More Information
Please contact Lillian Monaghan at 203-739-7898.
Register Now >>